The bRIGHT study aimed to evaluate the safety and effectiveness of the TriClip device in symptomatic patients with severe tricuspid regurgitation. In this touchCARDIO interview, we speak with Professor Erwan Donal (University Hospital of Rennes, Rennes, France) to discuss tricuspid transcatherter edge-to-edge repair, the difficulty in patient selection and the purpose and conclusions of the TriClip bRIGHT study.
The abstract entitled ‘Impact of coaptation gap location on procedural strategy and outcomes following tricuspid transcatheter edge-to-edge repair: insights from the TriClip bRIGHT study’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of tricuspid transcatherter edge-to-edge repair and its clinical impact? (0:40)
- What are the challenges of patient selection for this procedure? (2:03)
- What were the objectives of the TriClip bRIGHT study? (3:27)
- How did procedural and short-term outcomes vary according to coaptation gap location? (4:23)
- What were the conclusions of the investigators? (5:49)
Disclosures: Erwan Donal is on the advisory board for Abbott; GE healthcare and Pfizer and has received honoraria from Alnylam, Bristol Myer Squibb and Pfizer. CHU Rennes has a research contract with Abbott structural.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Devices here and Interventional Cardiology here
